Clearside Biomedical, Inc. (NASDAQ:CLSD) headquartered in Alpharetta, will host a conference call for the investment community to discuss the 3Q20 financial results on 10th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.clearsidebio.com
Earnings Expectation
Clearside Biomedical, Inc. is reporting third quarter financial results on Tuesday 10th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CLSD is expected to report 3Q20 loss of $ 0.12 per share from revenue of $ 1.82 million.
For the full year, analysts anticipate top line of $ 8.38 million, while looking forward to loss of $ 0.42 per share bottom line.
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
